Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen D Ryder

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
The Lancet. Gastroenterology & Hepatology|February 8, 2024
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnershipMohsan Subhani, Ashwin Dhanda, Adina Olaru, et al.
Alimentary Pharmacology & Therapeutics|October 2, 2023
In severe alcohol-related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL-8 and micro-RNAsLuke D Tyson, Stephen Atkinson, Robert W Hunter, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 18, 2014
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitisVlad Ratziu, Pierre Bedossa, Sven M Francque, et al.
Frontline Gastroenterology|October 26, 2017
The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS)Mark Hudson, Amr Radwan, Paola Di Maggio, et al.
Hepatology Communications|May 16, 2018
NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acidKathy L de Graaf, Geneviève Lapeyre, Florence Guilhot, et al.
Hepatology Communications|April 7, 2023
Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cellsVictoria Mulcahy, Evaggelia Liaskou, Jose-Ezequiel Martin, et al.
Plos One|January 23, 2023
Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virusAminata Sy, Leanne McCabe, Emma Hudson, et al.
Ebiomedicine|May 24, 2022
The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort studyDavid E J Jones, Aaron Wetten, Ben Barron-Millar, et al.
Gut Microbes|May 16, 2023
Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitisLaura Martinez-Gili, Alexandros Pechlivanis, Julie A K McDonald, et al.
Hepatology (Baltimore, Md.)|February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trialGraham R Foster, Kosh Agarwal, Matthew E Cramp, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
The Lancet. Gastroenterology & Hepatology|February 8, 2024
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnershipMohsan Subhani, Ashwin Dhanda, Adina Olaru, et al.
Alimentary Pharmacology & Therapeutics|October 2, 2023
In severe alcohol-related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL-8 and micro-RNAsLuke D Tyson, Stephen Atkinson, Robert W Hunter, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 18, 2014
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitisVlad Ratziu, Pierre Bedossa, Sven M Francque, et al.
Frontline Gastroenterology|October 26, 2017
The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS)Mark Hudson, Amr Radwan, Paola Di Maggio, et al.
Hepatology Communications|May 16, 2018
NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acidKathy L de Graaf, Geneviève Lapeyre, Florence Guilhot, et al.
Hepatology Communications|April 7, 2023
Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cellsVictoria Mulcahy, Evaggelia Liaskou, Jose-Ezequiel Martin, et al.
Plos One|January 23, 2023
Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virusAminata Sy, Leanne McCabe, Emma Hudson, et al.
Ebiomedicine|May 24, 2022
The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort studyDavid E J Jones, Aaron Wetten, Ben Barron-Millar, et al.
Gut Microbes|May 16, 2023
Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitisLaura Martinez-Gili, Alexandros Pechlivanis, Julie A K McDonald, et al.
Hepatology (Baltimore, Md.)|February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trialGraham R Foster, Kosh Agarwal, Matthew E Cramp, et al.
Pageof 8